Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body Dementia (VOCALE LBD)

7 de noviembre de 2026 actualizado por: Oleg Zaslavsky, University of Washington

Reducing Depression in Family Caregivers of Persons Living With Lewy Body Dementia Through Tailored Asynchronous Online Intervention.

This study tests whether a tailored, fully asynchronous online group intervention (VOCALE LBD) reduces depression in family caregivers of people with Lewy Body Dementia (LBD), compared to standard educational materials. LBD is the second most common form of degenerative dementia and causes distinct challenges, including visual hallucinations, REM sleep disorder, and severe motor symptoms, that are not addressed by generic caregiver interventions. Depression rates in LBD caregivers reach 40-50%, double the rate seen in Alzheimer's disease caregivers, yet no rigorous digital interventions exist specifically for this population. VOCALE LBD is a text-based, low-bandwidth platform (Discourse) that brings groups of 10-15 caregivers together in an 8-week moderated online community. Weekly topics address LBD-specific challenges (sleep problems, hallucinations, self-care) and problem-solving skills using the ADAPT method. A pilot study (n=54) showed strong effects on depressive symptoms (Cohen's d=0.54 at 1-month follow-up), near-perfect engagement, and high participant satisfaction. This RCT (N=220) will test efficacy, examine mechanisms of action (self-efficacy and problem-solving), and explore analytics approaches for pragmatic monitoring, laying groundwork for future implementation in clinics and community organizations.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Over 1.4 million people in the U.S. are diagnosed with Lewy Body Dementia (LBD). Up to 80% receive care from family members, yet family caregivers of people with LBD experience depression at rates (40-50%) double those of Alzheimer's disease caregivers. LBD's distinct features - visual hallucinations, REM sleep behavior disorder, cognitive fluctuations, and Parkinsonian motor symptoms - create caregiving demands not addressed by existing dementia caregiver interventions. Current pharmacological treatments for LBD are largely experimental, leaving families to manage severe behavioral and motor symptoms without adequate support. INTERVENTION: VOCALE LBD (Virtual Online Communities for Aging Life Experiences - Lewy Body Dementia) is a fully asynchronous, text-based online group intervention delivered via the Discourse platform. The 8-week program includes icebreaker activities followed by LBD-specific weekly topics (self-care, sleep problems, hallucinations and delusions) and problem-solving training using the ADAPT method (Adopting a positive attitude, Defining the problem, brainstorming Alternatives, Predicting consequences, Trying the solution). Groups of 10-15 caregivers are moderated by a licensed nurse or social worker (RN/LCSW), who logs in daily and facilitates discussions. The platform requires no video conferencing and is accessible via any internet-connected device. Loaner devices and digital literacy training are provided for participants who need them. STUDY DESIGN: Two-arm, randomized controlled trial. Participants are randomized 1:1 to (a) VOCALE LBD or (b) Standard of Care (SOC: NIA psychoeducational materials, LBDA resource list, problem-solving handouts). Assessment time points: baseline, post-intervention (week 8), and 6-month follow-up. Exit interviews are conducted at the end of the intervention. AIMS: Aim 1 tests whether VOCALE LBD reduces depressive symptoms (CES-D) compared to SOC at week 8, with sustained effect at 6 months. Aim 2 examines mechanisms - whether self-efficacy and problem-solving mediate outcomes (2a quantitative mediation; 2b qualitative analysis). Aim 3 explores pragmatic monitoring using user engagement analytics, natural language processing, and LLM-assisted moderator support tools. RECRUITMENT: Nationwide recruitment through the Lewy Body Dementia Association (LBDA) via eblasts, social media, support groups, and print materials. Additional outreach via Alzheimer.gov and national LBD caregiver web resources.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

220

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Oleg Zaslavsky, PhD, RN
  • Número de teléfono: (206) 849-3301
  • Correo electrónico: zaslav@uw.edu

Copia de seguridad de contactos de estudio

  • Nombre: Aimy Paulsen, MPH
  • Número de teléfono: (253) 693-8329
  • Correo electrónico: vocale-lbd@uw.edu

Ubicaciones de estudio

    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • Reclutamiento
        • University of Washington
        • Contacto:
          • Oleg Zaslavsky, PhD, RN
          • Número de teléfono: (206) 849-3301
          • Correo electrónico: zaslav@uw.edu
        • Contacto:
          • Aimy Paulsen, MPH
          • Número de teléfono: (253) 693-8329
          • Correo electrónico: vocale-lbd@uw.edu
        • Investigador principal:
          • Oleg Zaslavsky, PhD, RN

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Current family member or informal (unpaid) caregiver of a person with a confirmed diagnosis of Lewy Body Dementia (LBD) or LBD mixed pathology
  • Experiences depressive symptoms as defined by a score of 5 or higher on the Patient Health Questionnaire-9 (PHQ-9)
  • Able to read, write, and speak English
  • Has access to a device (computer, tablet, or smartphone) that can connect to the internet and be used for videoconferencing or phone calls, OR is interested in using a loaner device
  • Has an active email address OR is willing to create and use an email address prior to enrollment

Exclusion Criteria:

  • Active suicidal ideation as indicated by endorsement of PHQ-9 Item 9 (thoughts that you would be better off dead, or thoughts of hurting yourself)
  • Paid or professional caregiver (must be unpaid family/informal caregiver)
  • Unable to read, write, or speak English

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: VOCALE LBD

Participants in this arm receive the VOCALE LBD intervention: an 8-week, fully asynchronous, text-based online group program delivered via the Discourse platform. Groups of 10-15 participants are facilitated by trained moderators who log in daily. Weekly discussion topics address LBD-specific caregiving challenges (sleep problems, hallucinations and delusions) and problem-solving skills training using the ADAPT method. Participants are asked to make a minimum of three posts each week (e.g., adding a post, replying to two other users).

The 8-week VOCALE LBD intervention is delivered asynchronously via the Discourse online platform. The weekly curriculum includes: Pre-intervention (Icebreakers, Self-introductions); Week 1 (Sleep Problems); Week 2 (Hallucinations and Delusions); Week 3 (ADAPT - Positive Attitude); Week 4 (ADAPT - Define the Problem); Week 5 (ADAPT - Alternative Solutions); Week 6 (ADAPT - Plan); Week 7 (ADAPT - Try); Week 8 (Reflection and Wrap Up).

Otros nombres:
  • VOCALE LBD
  • Virtual Online Community
  • Asynchronous Online Group Intervention
Comparador activo: Standard of Care

NIA and LBDA psychoeducational materials on LBD and caregiving; LBDA resource list; problem-solving principles handout. Materials delivered via email.

NIA and LBDA psychoeducational materials on LBD and caregiving; LBDA resource list; problem-solving principles handout. Materials delivered via email or mail per participant preference.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Center for Epidemiologic Studies Depression Scale (CES-D)
Periodo de tiempo: Baseline (pre-randomization), Post-intervention (Week 8), 6-month follow-up

The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report questionnaire that evaluates the frequency of depressive symptoms experienced in the past week (including depressed mood, feelings of guilt/worthlessness, helplessness, and physical symptoms). Total scores range from 0 to 60. Higher scores indicate greater severity of depressive symptoms (worse outcome).

Baseline (pre-randomization), Post-intervention (Week 8), 6-month follow-up

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Short Zarit Caregiver Burden Interview (ZBI-12)
Periodo de tiempo: Baseline, Week 8, 6-month follow-up

The Short Zarit Caregiver Burden Interview (ZBI-12) is a 12-item self-report instrument that measures personal strain and role strain associated with caregiving. Total scores range from 0 to 48. Higher scores indicate greater caregiver burden (worse outcome).

Baseline, Week 8, 6-month follow-up
UCLA Loneliness Scale (3-Item Short Form)
Periodo de tiempo: Baseline, Week 8, 6-month follow-up

The UCLA Loneliness Scale (3-Item Short Form) is a 3-item self-report survey assessing subjective feelings of loneliness and social isolation. Total scores range from 3 to 9. Higher scores indicate greater loneliness and social isolation (worse outcome).

Baseline, Week 8, 6-month follow-up
Perceived Stress Scale (PSS-10)
Periodo de tiempo: Baseline, Week 8, 6-month follow-up

The Perceived Stress Scale (PSS-10) is a 10-item instrument measuring an individual's perception of stress and feelings of unpredictability, uncontrollability, and overload during the past month. Total scores range from 0 to 40. Higher scores indicate greater perceived stress (worse outcome).

Baseline, Week 8, 6-month follow-up
Medical Outcomes Study Social Support Survey (MOS-SSS)
Periodo de tiempo: Baseline, Week 5 (mid-intervention), Week 8, 6-month follow-up

The Medical Outcomes Study Social Support Survey (MOS-SSS) is a 19-item questionnaire evaluating multiple dimensions of social support (emotional/informational, tangible, affectionate, and positive social interaction). Raw total scores range from 19 to 95 (which can be transformed to an overall index score of 0 to 100). Higher scores indicate greater social support (better outcome).

Baseline, Week 5 (mid-intervention), Week 8, 6-month follow-up

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Social Problem-Solving Inventory-Revised (SPSI-R Short Form)
Periodo de tiempo: Baseline, Week 5, Week 8, 6-month follow-up

The Social Problem-Solving Inventory-Revised (SPSI-R:S) is a 25-item self-report instrument assessing cognitive and behavioral problem-solving orientations and skills across five subscales (Positive Problem Orientation, Negative Problem Orientation, Rational Problem Solving, Impulsivity/Carelessness Style, and Avoidance Style). Standardized total scores range from 0 to 20. Higher total scores indicate better social problem-solving skills (better outcome). Used as mechanistic measure.

Baseline, Week 5, Week 8, 6-month follow-up
General Self-Efficacy Scale (GSE)
Periodo de tiempo: Baseline, Week 5, Week 8, 6-month follow-up

The General Self-Efficacy Scale (GSE) is a 10-item self-report questionnaire assessing optimistic self-beliefs and confidence in coping with daily difficulties and novel situations. Total scores range from 10 to 40. Higher scores indicate greater general self-efficacy (better outcome).

Baseline, Week 5, Week 8, 6-month follow-up
Caregiver Self-Efficacy Scale (CSES-8)
Periodo de tiempo: Baseline, Week 5, Week 8, 6-month follow-up

The Caregiver Self-Efficacy Scale is an 8-item self-report questionnaire measuring caregiver confidence in managing caregiving demands, obtaining respite, and handling challenging behaviors. Total scores range from 0 to 100 (percent confidence). Higher scores indicate greater caregiver self-efficacy (better outcome).

Baseline, Week 5, Week 8, 6-month follow-up
User Engagement Scale (UES)
Periodo de tiempo: Week 8

The User Engagement Scale (UES) is a 31-item self-report survey characterizing the depth and quality of participant interactions with the online discussion platform across four subdomains (focused attention, perceived usability, aesthetic appeal, and reward). Mean item scores range from 1 to 5. Higher scores indicate greater platform engagement (better outcome).

Week 8
Benefits of Participating Scale
Periodo de tiempo: Week 8, 6-month follow-up

The Benefits of Participating Scale is a 4-item questionnaire evaluating perceived personal benefit and satisfaction with program participation (rated on a 3-point scale: 1 = Not at all, 2 = Some, 3 = A great deal). Total scores range from 4 to 12. Higher scores indicate greater perceived benefit and study satisfaction (better outcome).

Week 8, 6-month follow-up

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Oleg Zaslavsky, PhD, RN, University of Washington, School of Nursing

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

30 de noviembre de 2029

Finalización del estudio (Estimado)

30 de noviembre de 2030

Fechas de registro del estudio

Enviado por primera vez

3 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de junio de 2026

Publicado por primera vez (Actual)

9 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

7 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • STUDY00024227
  • 1R01MH139601-01A1 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data that underlie the results reported in publications (text, tables, figures, appendices) will be shared. Data will be made available 9 months following publication of the primary study results. Data will be deposited in an NIH-designated repository (e.g., NIMH Data Archive or ICPSR). Requests for data should include a data analysis plan and be submitted to the PI.

Marco de tiempo para compartir IPD

Beginning 9 months after publication of primary outcome results; available for 5 years.

Criterios de acceso compartido de IPD

Researchers who provide a methodologically sound data analysis plan. Proposals should be directed to zaslav@uw.edu. To gain access, data requestors will need to sign a data access agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .